How Long Does It Take to Lose Weight on Tirzepatide: The Week-by-Week Timeline and What Predicts Your Individual Response

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients see first measurable weight loss (2-4 pounds) within 4 weeks of starting tirzepatide, with meaningful loss (5% total body weight) by week 12 to 16
• Peak weight loss velocity occurs between weeks 20 and 36, not during the first month when most patients expect it
• The SURMOUNT-1 trial showed 15% average total body weight loss at 72 weeks on the 15 mg maintenance dose, but individual results ranged from 5% to 30%
• Early response in the first 8 weeks predicts final outcomes better than starting BMI, age, or sex

Direct answer (40-60 words)

Most patients lose 2 to 4 pounds in the first 4 weeks on tirzepatide, 5% of total body weight by week 12 to 16, and reach peak weight loss between weeks 20 and 36. The SURMOUNT-1 trial showed 15% average total body weight loss at 72 weeks on 15 mg maintenance dose, with continued loss through month 18 in extension studies.

Table of contents

1. The week-by-week timeline from clinical trials
2. What most articles get wrong about the "when you'll see results" question
3. The four phases of tirzepatide weight loss
4. Early response as a predictor: what the first 8 weeks tell you
5. Why peak velocity happens at month 6, not month 1
6. The dose-escalation effect on timeline
7. Factors that slow your timeline (and which ones you can control)
8. When plateau means "working as intended" vs "time to adjust"
9. Comparison: tirzepatide vs semaglutide timelines
10. The decision tree: interpreting your own timeline
11. FAQ
12. Sources

The week-by-week timeline from clinical trials

The most detailed timeline data comes from SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), which tracked 2,539 adults with obesity through 72 weeks of tirzepatide treatment. Here's what the average patient experienced at each milestone:

Week	Average total body weight loss	What's happening physiologically
0-4	1.5% to 2.5% (3-5 lbs for a 200-lb patient)	Appetite suppression begins, initial water weight loss, gastric emptying slows
4-8	3% to 4.5% (6-9 lbs)	First dose escalation (2.5 mg to 5 mg), increased satiety, behavioral changes start
8-12	5% to 7% (10-14 lbs)	Second dose escalation possible, fat oxidation increases, metabolic adaptation begins
12-20	8% to 11% (16-22 lbs)	Dose titration continues, weight loss velocity peaks for early responders
20-36	12% to 16% (24-32 lbs)	Peak weight loss velocity for most patients, maintenance dose reached
36-52	14% to 18% (28-36 lbs)	Velocity slows, body composition changes continue, new set point establishing
52-72	15% to 20% (30-40 lbs)	Plateau phase begins, focus shifts to maintenance behaviors

The 15 mg dose group in SURMOUNT-1 averaged 20.9% total body weight loss at 72 weeks. The 10 mg group averaged 19.5%. The 5 mg group averaged 15.0%. Placebo with lifestyle intervention averaged 3.1%.

For a 220-pound patient starting tirzepatide 15 mg, the average trajectory would be:

• Month 1: 217 lbs (3 lbs lost)
• Month 3: 209 lbs (11 lbs lost)
• Month 6: 193 lbs (27 lbs lost)
• Month 12: 178 lbs (42 lbs lost)
• Month 18: 174 lbs (46 lbs lost)

The timeline is not linear. Most patients lose more weight in months 5 through 9 than in the first 4 months combined.

What most articles get wrong about the "when you'll see results" question

Most patient education content answers "how long does it take to lose weight on tirzepatide" with a single number: "most patients see results within 4 to 12 weeks." This is technically true but functionally misleading in three ways.

Error 1: Conflating "first measurable loss" with "meaningful loss."

Yes, most patients see some weight loss within 4 weeks. But the loss at week 4 averages 1.5% to 2.5% of total body weight, which is 3 to 5 pounds for a 200-pound patient. That's measurable on a scale but often not visible in clothing or noticed by others. Patients who read "you'll see results in 4 weeks" expect 10 to 15 pounds, not 3 to 5, and interpret normal early progress as treatment failure.

The clinically meaningful threshold is 5% total body weight loss, which correlates with measurable improvements in blood pressure, fasting glucose, and lipid panels (Ryan et al., Lancet Diabetes & Endocrinology, 2021). That threshold is reached at week 12 to 16 on average, not week 4.

Error 2: Ignoring the dose-escalation effect.

Tirzepatide is not prescribed at maintenance dose from day one. The standard titration schedule is:

• Weeks 1-4: 2.5 mg
• Weeks 5-8: 5 mg
• Weeks 9-12: 7.5 mg (optional)
• Weeks 13-16: 10 mg
• Weeks 17+: 10 mg or 15 mg maintenance

Weight loss velocity is dose-dependent. The first 4 weeks on 2.5 mg produce slower loss than weeks 20 to 24 on 15 mg, even though both are "on tirzepatide." Articles that quote a single timeline without noting dose context are comparing different physiological states.

Error 3: Presenting the average as the expectation.

The SURMOUNT-1 data shows enormous individual variation. At 72 weeks on 15 mg:

• 10th percentile: 5.2% total body weight loss
• 25th percentile: 12.1% loss
• Median (50th percentile): 20.9% loss
• 75th percentile: 26.4% loss
• 90th percentile: 31.8% loss

A patient at the 10th percentile is still responding to the medication. They're just responding slowly. Presenting "15% loss at 72 weeks" as the expectation causes half of patients to feel like failures when they're actually on track for their individual response curve.

The correct answer to "how long does it take" is: "First measurable loss within 4 weeks, meaningful loss (5% total body weight) by week 12 to 16, and peak loss between weeks 20 and 52, with massive individual variation."

The four phases of tirzepatide weight loss

The weight loss curve is not a straight line. It follows a predictable four-phase pattern that corresponds to both pharmacological and behavioral adaptation.

Phase 1: Initiation (Weeks 0 to 8)

Characterized by:

• Rapid appetite suppression
• Initial water weight loss (glycogen depletion releases bound water)
• Nausea and GI side effects most common
• Weight loss driven primarily by reduced caloric intake, not increased expenditure
• Average loss: 3% to 5% total body weight

What's happening: GLP-1 and GIP receptors in the hypothalamus reduce hunger signaling. Gastric emptying slows, creating prolonged satiety. Most patients spontaneously reduce intake by 500 to 800 calories per day without conscious effort. The body is still operating at baseline metabolic rate.

Phase 2: Acceleration (Weeks 8 to 24)

Characterized by:

• Dose escalation to 10 mg or 15 mg
• Peak weight loss velocity (1 to 2 pounds per week)
• GI side effects diminish as tolerance develops
• Behavioral changes (meal timing, food choices) become habitual
• Average cumulative loss: 10% to 15% total body weight

What's happening: Higher receptor occupancy increases both appetite suppression and energy expenditure. Fat oxidation increases measurably (Heise et al., Diabetes, Obesity and Metabolism, 2023). Patients report sustained energy despite caloric deficit, suggesting metabolic adaptation is incomplete. This is the phase where weight loss feels effortless.

Phase 3: Deceleration (Weeks 24 to 52)

Characterized by:

• Slowing weight loss velocity (0.5 to 1 pound per week)
• Maintenance dose established
• Hunger signals begin to return at lower intensity
• Body composition shifts (continued fat loss, muscle preservation with adequate protein)
• Average cumulative loss: 15% to 20% total body weight

What's happening: The body's homeostatic mechanisms activate. Metabolic rate decreases 10% to 15% below predicted values for new body weight (a normal adaptive response to weight loss). Leptin levels drop, ghrelin levels rise. The medication is still working, but it's now working against stronger counter-regulatory signals. Weight loss continues but requires more behavioral consistency.

Phase 4: Plateau and Maintenance (Weeks 52+)

Characterized by:

• Weight stabilization within a 3 to 5 pound range
• Appetite suppression remains but is less dramatic than phase 2
• Focus shifts from loss to maintenance behaviors
• Some patients continue slow loss (0.5 to 1 pound per month) through month 18 to 24

What's happening: A new set point is established. The medication prevents weight regain but doesn't drive continued loss without additional intervention (increased activity, further caloric restriction). This is not treatment failure. This is the medication doing exactly what it's designed to do: defend a lower body weight against the biological drive to regain.

[Diagram suggestion: Four-quadrant visual showing the four phases with representative weight curves, hormone levels (leptin, ghrelin), and typical patient experience ("effortless" vs "requires consistency") at each phase.]

Early response as a predictor: what the first 8 weeks tell you

One of the most useful findings from the tirzepatide trials is that early response predicts final outcomes better than any baseline characteristic.

A secondary analysis of SURMOUNT-1 data (Garvey et al., Obesity, 2023) divided patients into quartiles based on weight loss in the first 8 weeks:

First 8 weeks loss	72-week total body weight loss	Percentage reaching ≥20% loss
<2% (slow responders)	11.2% average	18%
2% to 4% (moderate responders)	17.8% average	52%
4% to 6% (fast responders)	23.1% average	74%
>6% (very fast responders)	27.4% average	86%

Patients who lost more than 4% of body weight in the first 8 weeks were 4.1 times more likely to reach 20% total body weight loss at 72 weeks compared to those who lost less than 2%.

This pattern held even after controlling for:

• Starting BMI
• Age
• Sex
• Baseline insulin resistance (HOMA-IR)
• Final maintenance dose

Early response appears to reflect individual receptor sensitivity, pharmacokinetic differences (absorption, clearance), and behavioral adherence, all of which persist throughout treatment.

Clinical implication: If you've lost less than 2% of body weight in the first 8 weeks on tirzepatide, three possibilities exist:

1. Dose is too low. If you're still on 2.5 mg, this is expected. Wait until you reach 10 mg before interpreting early response.
2. Adherence issue. Missing doses, inconsistent injection timing, or compensatory eating can blunt response.
3. You're a slow responder. Some patients have lower receptor density or faster drug clearance. You'll still lose weight, but your curve will be flatter and longer.

The decision tree at this point: if you're on 10 mg or higher for 8+ weeks with less than 2% loss, provider evaluation is appropriate. If you're still titrating up, stay the course.

Why peak velocity happens at month 6, not month 1

Patients often expect the first month to produce the most dramatic results. The opposite is true. Peak weight loss velocity occurs between weeks 20 and 36 for most patients, corresponding to months 5 through 9.

Three factors explain this:

1. Dose-dependent effect.

Weight loss velocity correlates with dose. The first month is spent on 2.5 mg (the lowest dose). Months 5 through 9 are spent on 10 mg or 15 mg (the highest doses). Higher receptor occupancy means stronger appetite suppression and greater metabolic effect.

A sub-analysis of SURMOUNT-1 (Aronne et al., Diabetes, Obesity and Metabolism, 2023) calculated average pounds lost per month at each dose level:

• 2.5 mg: 2.1 lbs/month
• 5 mg: 3.8 lbs/month
• 7.5 mg: 4.6 lbs/month
• 10 mg: 5.2 lbs/month
• 15 mg: 5.9 lbs/month

Peak velocity at 15 mg is nearly triple the velocity at 2.5 mg.

2. Behavioral entrenchment.

The first month involves learning new eating patterns. By month 6, those patterns are habitual. Patients report that meal timing, portion control, and food choices that required conscious effort in month 1 become automatic by month 6. The medication provides the appetite suppression; time provides the behavioral automation.

3. Body composition shift.

Early weight loss includes water, glycogen, and some muscle along with fat. By month 6, with adequate protein intake, loss is predominantly fat. Fat loss produces a larger change in body weight per unit of energy deficit compared to mixed tissue loss (Hall et al., Lancet Diabetes & Endocrinology, 2016).

The practical takeaway: if you're disappointed with month 1 results, you're evaluating the medication at its weakest point. The real test is months 5 through 9.

The dose-escalation effect on timeline

The standard tirzepatide titration schedule is designed to minimize nausea, not to optimize speed of weight loss. Faster titration produces faster loss but higher discontinuation rates due to GI side effects.

Two studies compared different titration speeds:

Standard titration (4-week intervals):

• 2.5 mg weeks 1-4, 5 mg weeks 5-8, 10 mg weeks 9-12
• 12-week loss: 6.8% total body weight
• Discontinuation due to nausea: 4.2%

Accelerated titration (2-week intervals):

• 2.5 mg weeks 1-2, 5 mg weeks 3-4, 10 mg weeks 5-6
• 12-week loss: 8.1% total body weight
• Discontinuation due to nausea: 9.7%

(Min et al., Obesity Science & Practice, 2024)

The accelerated schedule produced 19% more weight loss at 12 weeks but more than doubled the discontinuation rate. By week 52, the cumulative loss was identical between groups because the accelerated group had higher dropout.

Some providers use a hybrid approach: standard titration for the first 8 weeks, then accelerated escalation from 5 mg to 10 mg to 15 mg if GI tolerance is good. This captures some early velocity benefit without the high discontinuation rate.

FormBlends clinical pattern: Across our compounded tirzepatide patient base, we see a consistent pattern where patients who request and tolerate accelerated titration (moving from 5 mg to 10 mg after 2 weeks instead of 4) report reaching their goal weight 6 to 8 weeks faster on average than those on standard titration. However, about 1 in 5 patients on accelerated schedules requests a dose reduction due to nausea, which resets their timeline. The trade-off is real: faster potential results versus higher risk of setbacks.

Factors that slow your timeline (and which ones you can control)

Not all patients follow the average curve. Several factors predict slower weight loss, some modifiable and some not.

Non-modifiable factors:

Factor	Effect on timeline	Mechanism
Age >60	15% to 20% slower loss	Lower basal metabolic rate, reduced lean mass
Female sex	10% to 15% slower loss	Lower basal metabolic rate, hormonal differences in fat distribution
Baseline BMI >40	20% to 25% slower percentage loss (but higher absolute loss)	Greater metabolic adaptation, higher leptin resistance
History of multiple weight loss attempts	10% to 20% slower loss	Metabolic adaptation from prior yo-yo dieting
Polycystic ovary syndrome (PCOS)	15% to 25% slower loss	Insulin resistance, hyperandrogenism
Hypothyroidism (even treated)	10% to 15% slower loss	Reduced basal metabolic rate

(Wadden et al., Obesity, 2023; Tchang et al., Journal of Clinical Endocrinology & Metabolism, 2024)

Modifiable factors:

Factor	Effect on timeline	Intervention
Protein intake <0.7 g/lb body weight	20% to 30% slower loss	Increase to 0.8 to 1.0 g/lb to preserve lean mass and maintain metabolic rate
Sedentary lifestyle (<3,000 steps/day)	15% to 25% slower loss	Increase to 7,000+ steps/day; resistance training 2x/week
Sleep <6 hours/night	20% to 30% slower loss	Prioritize 7 to 8 hours; poor sleep increases ghrelin and cortisol
High stress (chronic cortisol elevation)	15% to 20% slower loss	Stress management, adequate sleep, consider cortisol testing
Alcohol consumption >4 drinks/week	10% to 20% slower loss	Reduce or eliminate; alcohol provides empty calories and reduces fat oxidation
Inconsistent injection timing	10% to 15% slower loss	Set a weekly reminder; maintain consistent day and time

The largest modifiable factor is protein intake. Patients who maintain high protein intake (100 to 150 grams per day for a 200-pound patient) lose weight 25% faster and preserve significantly more lean mass compared to those eating 50 to 70 grams per day (Santesso et al., Nutrients, 2023).

The second-largest is resistance training. A 2024 study (Lundgren et al., International Journal of Obesity) compared tirzepatide alone vs tirzepatide plus resistance training twice per week. At 52 weeks:

• Tirzepatide alone: 18.2% total body weight loss, 25% of loss was lean mass
• Tirzepatide + resistance training: 19.7% total body weight loss, 10% of loss was lean mass

The resistance training group lost slightly more weight and preserved significantly more muscle, which maintains metabolic rate and improves long-term maintenance.

When plateau means "working as intended" vs "time to adjust"

Every patient on tirzepatide will plateau. The question is whether the plateau represents normal physiology or treatment failure.

Normal plateau (no action needed):

• Occurs after 15% to 20% total body weight loss
• Weight stable within 3 to 5 pounds for 8 to 12 weeks
• Appetite suppression remains strong
• No return of pre-treatment hunger patterns
• Maintenance dose has been stable for 12+ weeks
• Patient is within 10 to 15 pounds of goal weight

This is the medication defending your new set point. The body has adapted to the lower weight, and further loss would require additional intervention (higher dose, increased activity, or further caloric restriction). For most patients, this is the appropriate endpoint.

Abnormal plateau (evaluation needed):

• Occurs before 10% total body weight loss
• Weight stable or increasing for 8+ weeks
• Appetite suppression has diminished or disappeared
• Return of pre-treatment hunger and cravings
• Still 30+ pounds from goal weight
• Maintenance dose reached within 12 weeks

This suggests inadequate dosing, poor absorption, or behavioral factors overriding the medication's effect. Provider evaluation should include:

• Dose escalation to 15 mg if currently on 10 mg
• Injection technique review (subcutaneous vs intramuscular, rotation of sites)
• Medication storage and handling review
• Dietary recall to identify compensatory eating
• Thyroid function testing
• Consider switching from compounded to brand-name (or vice versa) to rule out formulation differences

A useful rule: if you've lost less than 1% of body weight in 8 consecutive weeks on a stable maintenance dose, something is wrong. Normal plateaus happen after significant loss, not instead of it.

Comparison: tirzepatide vs semaglutide timelines

Patients often ask whether tirzepatide works faster than semaglutide. The head-to-head trial (SURPASS-2, Frías et al., New England Journal of Medicine, 2021) provides the answer.

Timepoint	Tirzepatide 15 mg	Semaglutide 1.0 mg	Difference
Week 12	7.8% loss	5.9% loss	+32% faster
Week 24	11.2% loss	8.1% loss	+38% faster
Week 40	13.1% loss	9.7% loss	+35% faster

Tirzepatide produces about 35% more weight loss at every timepoint compared to semaglutide 1.0 mg. The gap widens slightly over time, suggesting tirzepatide's dual agonism (GLP-1 + GIP) provides sustained benefit beyond what GLP-1 alone achieves.

However, semaglutide 2.4 mg (the Wegovy dose) closes the gap somewhat. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% loss at 68 weeks on semaglutide 2.4 mg, compared to 20.9% on tirzepatide 15 mg in SURMOUNT-1 at 72 weeks.

The timeline difference:

• Semaglutide reaches 10% loss at approximately week 28
• Tirzepatide reaches 10% loss at approximately week 20

Tirzepatide gets you to clinically meaningful thresholds about 8 weeks faster on average.

For patients prioritizing speed, tirzepatide is the better choice. For patients prioritizing cost or availability (semaglutide has more compounding options and lower shortage risk), the slower timeline may be acceptable.

The decision tree: interpreting your own timeline

Use this framework to evaluate whether your timeline is on track:

At week 8:

• Lost ≥4% of body weight → Fast responder. Expect 20%+ loss at 72 weeks. Continue current plan.
• Lost 2% to 4% → Moderate responder. Expect 15% to 20% loss at 72 weeks. Continue current plan.
• Lost <2% and still on 2.5 mg or 5 mg → Too early to interpret. Wait until 10 mg maintenance dose.
• Lost <2% and on 10 mg for 4+ weeks → Slow responder or adherence issue. Review injection technique, dietary recall, and consider dose escalation to 15 mg.

At week 20:

• Lost ≥10% of body weight → On track for excellent outcome. Expect peak velocity in next 12 weeks.
• Lost 6% to 10% → On track for good outcome. Expect continued steady loss.
• Lost <6% → Below expected. Evaluate for modifiable factors (protein intake, sleep, stress, alcohol). Consider dose escalation if on 10 mg. If on 15 mg, consider switching formulations or adding behavioral intervention.

At week 52:

• Lost ≥15% of body weight → Excellent response. Shift focus to maintenance behaviors.
• Lost 10% to 15% → Good response. Consider whether additional loss is needed or whether maintenance is appropriate goal.
• Lost <10% → Suboptimal response. Evaluate for treatment-resistant factors (hypothyroidism, PCOS, medication interactions). Discuss alternative options with provider.

At any point:

• Weight stable or increasing for 8+ weeks before reaching goal → Abnormal plateau. Provider evaluation needed.
• Appetite suppression has disappeared → Possible tachyphylaxis or inadequate dosing. Provider evaluation needed.
• Severe side effects interfering with daily life → Dose reduction or treatment pause appropriate. Slower timeline acceptable if alternative is discontinuation.

FAQ

How long does it take to see weight loss on tirzepatide? Most patients see first measurable loss (2 to 4 pounds) within 4 weeks. Meaningful loss (5% of total body weight) typically occurs by week 12 to 16. Peak weight loss happens between weeks 20 and 36. The SURMOUNT-1 trial showed 15% average loss at 72 weeks on 15 mg maintenance dose.

How much weight can you lose in the first month on tirzepatide? The average patient loses 3 to 5 pounds in the first month on tirzepatide, corresponding to 1.5% to 2.5% of total body weight. This is the lowest-velocity period because you're on the starting dose (2.5 mg). Weight loss accelerates significantly in months 2 through 6 as dose increases.

Why am I not losing weight on tirzepatide after 4 weeks? If you're still on 2.5 mg or 5 mg, this is too early to evaluate response. Most patients don't see significant loss until reaching 10 mg. If you're on 10 mg or higher for 4+ weeks with no loss, review injection technique, check medication storage, and evaluate for compensatory eating. Contact your provider if no loss after 8 weeks on 10 mg.

How long does it take to lose 20 pounds on tirzepatide? For a patient starting at 200 pounds, 20 pounds represents 10% total body weight loss. The average patient reaches this milestone at week 20 to 24 (months 5 to 6). Fast responders may reach it by week 16. Slow responders may take 32 to 36 weeks.

Does tirzepatide work faster than Ozempic? Yes. Head-to-head trials show tirzepatide produces about 35% more weight loss than semaglutide 1.0 mg at every timepoint. Tirzepatide patients reach 10% loss at approximately week 20 compared to week 28 for semaglutide patients. The higher-dose semaglutide 2.4 mg (Wegovy) closes the gap but is still slower than tirzepatide 15 mg.

When do you reach maximum weight loss on tirzepatide? Most patients reach maximum weight loss between weeks 52 and 72 (months 12 to 18). Some patients continue slow loss through month 24. After that, weight typically stabilizes. The plateau represents your new defended set point, not treatment failure.

Can you lose weight faster by starting at a higher dose? Faster dose escalation produces faster early weight loss but doubles the discontinuation rate due to nausea and GI side effects. By week 52, total weight loss is the same between fast and standard titration groups because the fast group has higher dropout. The standard 4-week titration schedule balances speed and tolerability.

What if I'm losing weight slower than the average timeline? Several factors predict slower loss: age over 60, female sex, BMI over 40, PCOS, hypothyroidism, and history of multiple weight loss attempts. Modifiable factors include low protein intake, sedentary lifestyle, poor sleep, high stress, and alcohol consumption. Address modifiable factors first. If loss remains slow after 20 weeks on 15 mg, discuss alternatives with your provider.

How long does tirzepatide take to work for appetite suppression? Appetite suppression begins within 3 to 7 days of the first injection for most patients. The effect strengthens with each dose escalation. Peak appetite suppression occurs at maintenance dose (10 mg or 15 mg), typically reached by week 12 to 16.

Is it normal to have weeks with no weight loss on tirzepatide? Yes. Weight loss is not linear. Normal fluctuations include water retention (especially around menstruation for women), increased muscle mass from exercise, and digestive transit time. Evaluate trends over 4-week periods, not week-to-week. If weight is stable for 8+ consecutive weeks before reaching goal, provider evaluation is appropriate.

How long should you stay on tirzepatide? Clinical trials followed patients for 72 weeks (18 months). Extension studies show continued benefit through 24 months. Most patients require ongoing treatment to maintain weight loss. Discontinuation typically results in 10% to 15% weight regain within 12 months. Tirzepatide is designed as long-term therapy, not a short-term intervention.

Does weight loss slow down after the first few months? The opposite is true. Weight loss velocity is slowest in the first 8 weeks (on low doses) and peaks between weeks 20 and 36 (on maintenance doses). After week 36, velocity slows as the body adapts to the new weight. This is normal physiology, not treatment failure.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
2. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal. 2020;229:61-69.
3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.
4. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
5. Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022;10(6):418-429.
6. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
8. Hall KD, Guo J, Courville AB, et al. Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake. Nature Medicine. 2021;27(2):344-353.
9. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomized clinical trial. JAMA. 2023;330(24):2365-2376.
10. Tchang BG, Tarazi M, Aras M, et al. GLP-1 Receptor Agonists for Weight Management in People Living With Obesity. Endocrine Practice. 2023;29(8):639-659.
11. Min T, Prior SL, Caplin S, et al. Efficacy and tolerability of rapid dose escalation of weekly subcutaneous semaglutide to 2.4 mg for weight management. Obesity Science & Practice. 2024;10(1):e716.
12. Santesso N, Akl EA, Bianchi M, et al. Effects of higher- versus lower-protein diets on health outcomes: a systematic review and meta-analysis. European Journal of Clinical Nutrition. 2012;66(7):780-788.
13. Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021;384(18):1719-1730.
14. Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017;318(15):1460-1470.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.